BridgeMD
New treatment option for Glaucoma, Primary Open Angle
Official title Adaptive Optics Retinal Imaging
ClinicalTrials.gov ID: NCT05370287
What this study is testing
- What it's testing
- The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 and older. Healthy volunteers may be eligible.
You may be able to join if
- Are 21 years of age or older.
- Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam).
- Have the ability to understand and sign an informed consent.
- Have been diagnosed with POAG (cohort 2).
You likely can't join if
- Are under 21 years of age.
- Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity).
- Have visual correction outside of the range +4 diopters (D) to -8 D.
- Have a history of adverse reaction to mydriatic drops.
- Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG).
- Do not meet the criteria for POAG as defined by the American Academy of Ophthalmology Practice Patterns (cohort 2)
See the full eligibility criteria
- Are 21 years of age or older.
- Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam).
- Have the ability to understand and sign an informed consent.
- Have been diagnosed with POAG (cohort 2).
- Are under 21 years of age.
- Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity).
- Have visual correction outside of the range +4 diopters (D) to -8 D.
- Have a history of adverse reaction to mydriatic drops.
- Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG).
- Do not meet the criteria for POAG as defined by the American Academy of Ophthalmology Practice Patterns (cohort 2)
- Have any health conditions that would contraindicate oxygen supplementation, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, or any other obstructive or restrictive lung disease (RBF...
- Have a dependency on oxygen support or a baseline oxygen saturation \<95% (RBF experiment participants only).
- Have tested positive for COVID-19 at initial enrollment or have acute or chronic photophobia as a result of contraction.
- Are working under the direct supervision of Dr. Hammer.
The study team makes the final eligibility decision.
Where it's taking place
- Silver Spring, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 21 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Silver Spring, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.